RxSight, Inc. Hits 52-Week Low at USD 4.93 Amidst Ongoing Struggles

RxSight, Inc., a microcap company in the Electronics & Appliances industry, has reached a new 52-week low of USD 4.93 as of June 2, 2026. This significant decline marks a stark contrast to its 52-week high of USD 16.36, highlighting a challenging year for the company. Over the past year, RxSight has experienced a dramatic performance drop of 91.62%, significantly underperforming the S&P 500, which has gained 28.2% during the same period. The company's financial metrics reflect ongoing difficulties, with negative results reported for the last four consecutive quarters. Key indicators such as the inventory turnover ratio have reached a low of 1 time, while the debtors turnover ratio stands at 4.77 times. Additionally, net sales have fallen by 18.48%, further emphasizing the company's struggles. With a market capitalization of USD 309 million, RxSight's financial health is under scrutiny, as evidenced by a return on equity of -12.95% and a debt-to-equity ratio of -0.82. The lack of a dividend yield and the absence of a price-to-earnings ratio indicate the company's loss-making status, contributing to its current market position.